Loading...
Loading...
OTLK| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 19.5M |
| Operating I/L | -19.6M |
| Other Income/Expense | 64.0M |
| Interest Income | 0.4M |
| Pretax | 44.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 44.4M |
Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company specializing in the development and commercialization of monoclonal antibodies for ophthalmic indications. Its primary revenue-generating product candidate is ONS-5010, an ophthalmic formulation of bevacizumab, currently in Phase-III clinical trials for treating wet age-related macular degeneration and other retina diseases. The company has collaboration and license agreements with several pharmaceutical entities, enabling it to leverage its product pipeline. Outlook Therapeutics, Inc. focuses on monetizing its innovative therapies to address unmet medical needs in the ophthalmic space.
